2 hours agoBusiness
30LENS
11 SourcesDelhi, India
thebalanced.newsMixed Q4 FY26 Results: Gains for PhysicsWallah, Sun Pharma; Losses for Utkarsh SFB, Jyothy Labs
Several Indian companies reported mixed financial and market performances in Q4 FY26. PhysicsWallah gained after HSBC initiated a 'Buy' rating, citing strong demand in education. Sun Pharma surged following its acquisition of Organon. Samvardhana Motherson showed technical strength, while Jyothy Labs shares fell after Henkel ended key brand licensing. Kewal Kiran Clothing and Sahyadri Industries posted profit growth, whereas Utkarsh Small Finance Bank and Aarti Surfactants reported losses. Piramal Pharma received a US FDA Form-483 with observations but no data integrity issues. Northern Arc Capital saw a significant profit rise, and Pidilite managed margin pressures amid raw material cost inflation.
Political Bias
0%100%0%
Sentiment
58%
AI Analysis
Political bias across 11 sources
● Left 0%● Center 100%● Right 0%
The article group primarily presents corporate financial and market updates without explicit political framing. Coverage focuses on company performance, acquisitions, regulatory developments, and market reactions. Perspectives include brokerage analyses, company statements, and regulatory findings, reflecting a business-centric viewpoint without partisan or ideological bias.
Sentiment — Neutral (58/100)
The overall sentiment is mixed, reflecting positive earnings and stock gains for some companies alongside losses and regulatory challenges for others. Reports balance optimism from growth and acquisitions with caution over profit declines and operational issues. The tone remains factual and neutral, avoiding emotional or sensational language.
How 11 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.
Coverage timeline
mint broke this story on 11 May, 01:54 am. Other outlets followed.
- 1mint11 May, 01:54 amPidilite walks pricing tightrope as raw material costs soar Stock Market News
- 2businessstandard11 May, 05:02 amUtkarsh SFB slumps after dismal Q4 performance
- 3businessstandard11 May, 05:57 amPiramal Pharma's Sellersville unit gets Form-483 with three observations from US FDA
- 4businessstandard11 May, 05:57 amNorthern Arc Capital climbs after Q4 PAT surges over three-fold to Rs 132 cr
- 5businessstandard11 May, 06:34 amPhysicsWallah gains 6 in trade; HSBC Global Investment initiates 'Buy'
- 6businessstandard11 May, 06:44 amSamvardhana Motherson can rally another 15 , says Choice Equity Broking
- 7freepressjournal11 May, 06:50 amSahyadri Industries Q4 Profit Jumps 147 To 10.6 Crore, Revenue Rises 29
- 8businessstandard11 May, 06:51 amAarti Surfactants slumps after Q4 PAT tanks 57 YoY to Rs 4 cr
- 9businessstandard11 May, 06:51 amKewal Kiran Clothing clocks over 14 YoY growth in Q4 PAT
- 10businessstandard11 May, 06:55 amOrganon deal impact: Sun Pharma surges 16 in 10 days, nears record high
Lens Score breakdown
30/100
Public interest0/100
Coverage gap60%
Well-covered story — coverage matches public importance.
Who's involved
Institutions and figures named across source coverage.
Corporate
HenkelSun Pharmaceutical IndustriesOrganonPidilite IndustriesPiramal PharmaAarti SurfactantsUtkarsh Small Finance BankEquirus SecuritiesKewal Kiran ClothingNorthern Arc CapitalSahyadri Industries LtdPhysicsWallahJyothy LabsHSBC Global Investment ResearchMotilal Oswal Financial ServicesMerckSamvardhana Motherson InternationalChoice Equity Broking
Enforcement
United States Food and Drug Administration
Story context
- Category
- Business
- Location
- Delhi, India
- Sources analysed
- 11
- Last analysed
- 11 May 2026
- Key entities
- Indian rupeeBSE SENSEXCroreNet incomeBrokerIranIndiaEquity (finance)Valuation (finance)Tata GroupHSBCEarnings before interest, taxes, depreciation, and amortization
Related Coverage
Select a news story to see related coverage from other media outlets.